Abstract
Purpose :
To compare outcomes of 360° canaloplasty/goniotomy using the OMNI™ device to 360° canaloplasty/goniotomy using the iTrack™.
Methods :
A retrospective comparative study was conducted at a tertiary care center, reviewing 406 visits made by 65 patients who had undergone either OMNI™ or iTrack™ 360° canaloplasty/goniotomy between July 2020 and October 2023. Two Kaplan-Meier curves (KM) assessed survival with ≤ baseline meds while maintaining (1) [GS - Goal Success] IOP ≤ goal IOP or (2) [QS - Qualified Success] IOP reduction ≥ 20% with 5 mmHg ≤ IOP ≤ 21 mmHg for at least two consecutive visits.
Results :
Thirty-eight patients had OMNI™ and 30 underwent iTrack™. The most common glaucoma type in both groups was primary open-angle glaucoma (45% in OMNI™ vs. 50% in iTrack™; p=0.12). Both groups had similar baseline demographics except for baseline IOP and number of medications. The mean preoperative IOP was 18.83 ± 5.51 mmHg on 3.34 ± 1.07 medications in OMNI™ and 20.88 ± 5.92 mmHg on 2.90 ± 1.12 medications in iTrack™ (p=0. 0.088 for IOP; p=0.042 for medications). Under QS, there was a trend toward higher survival rates in the OMNI™ group at POM6 (62% vs. 51%; p=0.097). Under GS, the success rates were not statistically significantly different between groups at POM6 (97% in OMNI™ vs 77% iTrack™; p=0.29).
Conclusions :
Both OMNI™ and iTrack™ confered similar 360° canaloplasty/goniotomy success rates, with a trend toward more favorable QS success rates in the OMNI™ group.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.